Tech stock hits 52-week high at 72.39 USD

The tech stock of Bio-Techne Corp has hit a 52-week high, trading at 72.39 USD. This price point marks a 23% gain for the year, with the company's market capitalization standing at $11.27 billion. The stock has seen a 34.94% increase over the past year, though InvestingPro analysis suggests it may be overvalued. The share price rise highlights investor confidence in the company's performance and potential for the future.

For a more detailed analysis, readers can refer to the PRO Research Report on TECH, available among 1,400+ US equities on InvestingPro. Stakeholders are currently observing market trends and the company's developments that might affect its status. Recently, Bio-Techne reported its fourth-quarter 2026 results, meeting earnings expectations and exceeding revenue targets with $321.2 million in revenue.

This represents a 1% reported growth and a 3% organic increase compared to the same period last year, though a 2% dip was due to the sale of a business unit. The company is also undergoing a potential acquisition by Merck KGaA, Darmstadt, Germany. These factors and performance metrics are vital for investors to consider.